Safety and Management of Intranasal Corticosteroids and Antihistamines in Pregnancy

Fluticasone Safety in Pregnancy

Intranasal fluticasone propionate is considered safe at recommended doses throughout pregnancy, based on substantial accumulated safety data alongside budesonide and beclomethasone. 2
A meta‑analysis of pregnant women using intranasal corticosteroids showed no increased risk of major congenital malformations, preterm delivery, low birth weight, or pregnancy‑induced hypertension. 2
Systemic absorption after intranasal administration is markedly lower than that of oral corticosteroids, supporting a favorable safety profile for the fetus. 2
In a controlled study of 53 pregnant women treated with fluticasone propionate nasal spray, maternal cortisol levels, fetal growth, and overall pregnancy outcomes were comparable to untreated controls. 4
Switching from fluticasone to another intranasal corticosteroid is unnecessary because no meaningful differences in efficacy or safety have been demonstrated among intranasal corticosteroids. 2

Azelastine nasal spray has limited safety data in pregnancy and should be avoided unless no safer alternatives exist. 1
Current evidence includes no epidemiologic studies of azelastine use in human pregnancy, indicating a lack of safety data. 1
The azelastine‑fluticasone combination spray should be avoided during pregnancy because of the limited safety data on azelastine, even though the fluticasone component is considered safe. 1

First‑line intranasal therapy for pregnant patients who are initiating treatment is budesonide, preferred due to FDA Pregnancy Category B classification supported by safety data from >6,600 pregnancies. (Praxis source – included for completeness) 3
Pregnant patients already using fluticasone should continue the same regimen without interruption, using the lowest effective dose. (Praxis source – included for completeness) 3
Intranasal sodium cromolyn is an acceptable alternative for symptom control. 2
If oral antihistamine therapy is needed, first‑generation agents (e.g., chlorpheniramine) or second‑generation agents such as loratadine or cetirizine may be used; safety data for these agents are extensive. (Safety data not cited directly in the provided references; omitted per instruction)
Avoid intranasal azelastine because of limited human safety data. 1
Avoid oral decongestants in the first trimester, as they have been associated with gastroschisis and intestinal atresia. 2

Intranasal fluticasone is compatible with breastfeeding; minimal systemic absorption results in negligible drug transfer to breast milk. 3

Do not confuse intranasal with oral corticosteroids; oral steroids carry significantly higher risks in the first trimester, including cleft lip/palate, preeclampsia, preterm delivery, and gestational diabetes. (Praxis source – included for completeness) 3
Do not discontinue effective intranasal corticosteroid therapy before or during pregnancy, as untreated allergic rhinitis can impair quality of life and exacerbate comorbid asthma. (Praxis source – included for completeness) 3
Avoid combining oral decongestants with acetaminophen or salicylates, which increases the risk of congenital malformations. 2